

Distribution Date: June 01, 2023

TO: ALL NATIONAL CANCER CLINICAL TRIALS NETWORK (NCTN) MEMBERS
FROM SWOG Operations Office (E-mail: protocols@swog.org)
: RE: Cisplatin Shortage

MEMORANDUM- - Cisplatin Shortage

This memorandum has been prepared to advise sites about SWOG recommendations in light of the recent nationwide cisplatin shortage. Please ensure your site has enough cisplatin accessible for a full course of protocol treatment, prior to registering a patient who intends to receive cisplatin as required treatment, or as their chemotherapy regimen of choice on a SWOG protocol.

The FDA website on drug shortages (<https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages>) indicates this shortage may be resolved soon; however, your institution may or may not be able to obtain sufficient cisplatin for patients enrolled on SWOG trials. For trials where treatment may be directly impacted upon by this shortage, we have distributed study-specific guidance memoranda.

In general, we encourage sites to follow ASCO recommendations (<https://old-prod.asco.org/practice-patients/practice-support/drug-shortages>) for clinical management in the event of antineoplastic agents in limited supply – with the additional caveat that obtaining supply for patients already on specified protocol treatment using these agents be considered highest priority. Changes in agents, dose reductions or changes in cycle length may be considered only if specifically allowed in the protocol document or associated guidance.

This memorandum serves to notify the NCI and SWOG Statistics and Data Management Center.

cc: PROTOCOL & INFORMATION OFFICE